CN107496411A - The medicinal usage of fisetin - Google Patents
The medicinal usage of fisetin Download PDFInfo
- Publication number
- CN107496411A CN107496411A CN201710859001.5A CN201710859001A CN107496411A CN 107496411 A CN107496411 A CN 107496411A CN 201710859001 A CN201710859001 A CN 201710859001A CN 107496411 A CN107496411 A CN 107496411A
- Authority
- CN
- China
- Prior art keywords
- dpp
- fisetin
- compound
- medicinal usage
- technical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Abstract
The title of the present invention is the medicinal usage of fisetin.Affiliated technical field is medical science.The technical problems to be solved by the invention are to be related to fisetin or its pharmaceutically acceptable solvate and its purposes as therapeutic agent especially as inhibitors of dipeptidyl IV.The main points of the technical scheme of the technical problems to be solved by the invention are test of the compound to DPP IV enzyme inhibition activities.
Description
Technical field
The present invention relates to pharmaceutical technology field, and specifically, the present invention relates to compound fisetin to be used as dipeptidyl peptidase
The medicinal usage of IV (DPP-IV) inhibitor.
Background technology
DPP IV (IUBMB enzyme nomenclature EC.3.4.14.5) is a kind of II types memebrane protein, in the literature with a variety of
Title refers to, including DPP4, DP4, DAP-IV, FAP β, ADCP 2, ABP
(ADAbp), bis- peptidyls of Dipeptidylaminopeptidase IV, Xaa-Pro--aminopeptidase, Gly-Pro naphthyls amidase, rear proline
(postproline) Dipeptidylaminopeptidase IV, lymphocyte antigen CD26, glycoprotein GP110, DPP IV, sweet ammonia
Acyl Prolyl iminopeptidase, glycyl Prolyl iminopeptidase, X- prolyl pipeptidyl bases aminopeptidase, pepX, HLA
CD26, glycylprolyl Dipeptidylaminopeptidase, two peptidyl-peptide hydrolases, glycylprolyl aminopeptidase, two peptidyls-
Aminopeptidase IV, DPPIV/CD26, aminoacyl-prolyl pipeptidyl base aminopeptidase, T cell triggering molecule Tp103, X-
PDAP.DPP IV is referred to herein as " DPP-IV ".
DPP-IV is a kind of non-classical serine aminopeptidase, and it is removed from the amino terminal (N- ends) of peptide and protein
Remove Xaa-Pro dipeptides.Some naturally occurring peptides are also it has been reported that the DPP-IV dependences of X-Gly or X-Ser type dipeptides are slow
Release.
The present invention relates to the chemical combination that can suppress dipeptidyl peptidase-IV (DipeptidylpeptidaseIV, DPP-IV) activity
Thing and/or pharmaceutically acceptable solvate, this kind of compound can be used for treat diabetes, as diabetes B, hyperglycaemia,
Metabolic syndrome, hyperinsulinemia, obesity, angiocardiopathy and abnormal such as atherosclerosis, cranial vascular disease, maincenter god
Through systemic disease or abnormal including schizophrenia, anxiety disorder, Bipolar depression, depression, insomnia, cognitive disorder, stomach and intestine
Disease and exception, cancer, inflammation and inflammatory disease, respiratory disease and exception, skeletal muscle is abnormal, osteoporosis, climacteric
Symptom or exception, periodontal disease such as gingivitis, and various immunoregulatory disorders.
DPP-IV belongs to serine peptide enzyme family, belong to together the family also have DPP2, DPP8, DPP9, FAP and
POP etc..Animal model experiment result shows that such as anaemia, alopecia, decrease of platelet and splenomegaly can be caused by suppressing DPP8/9
Deng toxic reaction [Lankas GR, Leiting B, et al.Dipeptidyl peptidase IV inhibition for
the treatment of type2diabetes:potential importance of selectivity over
dipeptidyl peptidases8and9.Diabetes,2005,54:2988-2994].Therefore, for the single targets of DPP-IV
The design and significant [Bhumika DP, the ManJunath DG.Recent of exploitation for the selective depressant selected
approaches to medicinal chemistry and therapeutic potential of dipeptidyl
peptidase-4(DPP-4)inhibitors.European Journal of Medicinal Chemistry,2014,74:
574-605], this is also the difficult point and key point of new selective DPP-IV inhibitor research and development.
Therefore, this area still needs the strong selective DPP-IV inhibitors of structure novelty, activity to meet clinical treatment
Demand.
The content of the invention
DPP IV (Dipeptidyl peptidase IV, DPP-IV, CD26, EC 3.4.14.5) is a kind of energy
The serine protease of specific for hydrolysis polypeptide or protein N-terminal Xaa-Pro or Xaa-Ala dipeptides.DPP-IV is atypia
Serine protease, the Ser-Asp-His catalytic triads in its C-terminal region are different from typical serine protease, are backward
Arrangement.DPP-IV is II type integral membrane proteins, is distributed widely in mammal and respectively organizes.DPP-IV is small in intestines, liver, kidney near-end
Pipe, prostate, the differentiation surface epithelial cell of corpus luteum and leukocyte sub-type such as lymphocyte and Expression of Macrophages.Deposited in serum
In DPP-IV soluble protein form, its 26S Proteasome Structure and Function is identical with embrane-associated protein form but lacks hydrophobic transmembrane structure
Domain.
Diabetes B and fat attractive therapy can be turned into by suppressing DPP-IV.Although DPP-IV inhibitor energy
The sugar tolerance of diabetes B patient is effectively improved, but the half-life period of many inhibitor is shorter, or toxicity is larger.Therefore, it is necessary to open
Hair has more the DPP-IV of advantage in pharmaceutical activity, stability, selectivity, toxicity, pharmacokinetics or medicine at least one aspect of characteristic
Inhibitor is treated for diabetes B.Therefore, the invention provides a kind of novel DPP-IV inhibitors.
Embodiment
Following test example is for illustrating the present invention.
Compound fisetin (CAS used in the present invention:345909-34-4) obtained by mm Suppliers.
Biological assessment
Test example 1
The compounds of this invention is tested DPP-IV enzyme inhibition activities：
Instrument:
ELIASA, Envision (PerkinElmer, USA)
Material:
People source DPP-IV, obtained to be expressed using baculovirus expression system in insect cell.
Substrate, Ala-Pro-AMC.
Process:
DPP-IV can the ultraviolet excitation production of specific for hydrolysis substrate A la-Pro-AMC generations product AMC, AMC through 355nm
Raw 460nm transmitting light, fluorescent value linear change at 460nm wavelength, is calculated DPP4 activity in dynamic cooling water of units of measurement time.
Experiment is using MERK-0431 as control compound.
Sample is dissolved with DMSO, Cord blood, and concentration controls of the DMSO in final system is not influenceing detection activity
Within the scope of.
Compound MERK-0431 is that IC50 [nM] is 17.57 to DPP-IV inhibitory action.
Compound fisetin is 55.7% to DPP-IV inhibitory action when concentration is 20 μ g/mL.
Conclusion：Compound fisetin in the present invention has certain inhibitory action to DPP-IV enzymes.
The present invention can be summarized with others without prejudice to the concrete form of the spirit or essential characteristics of the present invention.Therefore, nothing
By from the point of view of which point, the embodiment above of the invention can only all be considered the description of the invention and can not limit this hair
It is bright.
Claims (1)
1. application of the compound fisetin in DPP IV (DPP-IV) inhibitor medicaments are prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710859001.5A CN107496411A (en) | 2017-09-21 | 2017-09-21 | The medicinal usage of fisetin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710859001.5A CN107496411A (en) | 2017-09-21 | 2017-09-21 | The medicinal usage of fisetin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107496411A true CN107496411A (en) | 2017-12-22 |
Family
ID=60698505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710859001.5A Pending CN107496411A (en) | 2017-09-21 | 2017-09-21 | The medicinal usage of fisetin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107496411A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101247793A (en) * | 2003-12-29 | 2008-08-20 | 哈佛大学校长及研究员协会 | Compositions for treating or preventing obesity and insulin resistance disorders |
-
2017
- 2017-09-21 CN CN201710859001.5A patent/CN107496411A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101247793A (en) * | 2003-12-29 | 2008-08-20 | 哈佛大学校长及研究员协会 | Compositions for treating or preventing obesity and insulin resistance disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107595833A (en) | The medicinal usage of cedrin | |
| CN107789346A (en) | The medicinal usage of texifolin | |
| CN107595835A (en) | The medicinal usage of Meciadanol | |
| CN107823206A (en) | The medicinal usage of bicuculline | |
| CN107569479A (en) | The medicinal usage of diosmetin | |
| CN107496412A (en) | The medicinal usage of senensetin | |
| CN107823203A (en) | Hipeastrum vittalum (L Her.) Herb.- Amaryllisvittata Ait determines the medicinal usage of alkali | |
| CN107233345A (en) | The medicinal usage of rutaecarpin | |
| CN107260737A (en) | The medicinal usage of corypalmine | |
| CN107375266A (en) | The medicinal usage of wogonin | |
| CN107714690A (en) | The medicinal usage of dihydromyricetin | |
| CN107375265A (en) | The medicinal usage of rhamnetin | |
| CN107496418A (en) | The medicinal usage of Bergenin | |
| CN107115346A (en) | The medicinal usage of Celastrol | |
| CN107496409A (en) | The medicinal usage of Chrysin | |
| CN107349201A (en) | The medicinal usage of epiberberine | |
| CN107496411A (en) | The medicinal usage of fisetin | |
| CN107550901A (en) | The medicinal usage of robinetin | |
| CN107661345A (en) | The medicinal usage of cassythicine | |
| CN107496410A (en) | The medicinal usage of robinetin | |
| CN107496414A (en) | The medicinal usage of tamarixetin | |
| CN107375268A (en) | The medicinal usage of azaleatin | |
| CN107496408A (en) | The medicinal usage of Norwogonin | |
| CN107397742A (en) | The medicinal usage of apiolin | |
| CN107661334A (en) | The medicinal usage of reticuline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171222 |